ANALYSIS OF THE PREVALENCE AND EXPERIENCE OF TREATMENT OF ALLERGIC DISEASES OF THE RESPIRATORY TRACT IN MONGOLIA



Cite item

Full Text

Abstract

Allergic diseases of the respiratory tract (allergic rhinitis and bronchial asthma) are the leading pathology in therapeutic practice. The results of a meta-analysis in the East Asian region showed that the overall prevalence of bronchial asthma and allergic rhinitis with bronchial asthma was 10.17% and 38.97%, respectively. On the territory of Mongolia there are 2883 plant species belonging to 662 genera and 128 families. In this regard, given the climatic and geographical features of Mongolia, the flowering and pallination season is long, which affects the quality of life of patients with allergic diseases.

The purpose of the study is to analyze the prevalence and incidence of allergic rhinitis and bronchial asthma in Mongolia and present the experience of treatment with Antipollin.

Methods: the study was conducted in Ulaanbaatar, Darkhan and Sukhbaatar for 2019-2022. Based on the data obtained, the following statistical indicators were calculated: incidence (cumulative incidence) per 1000 patients, prevalence (prevalence) for specific annual indicators and age groups.

Results: the cumulative incidence of allergic rhinitis for the fourth quarter of 2022 was determined to be from 28.9‰ to 43.92‰, the cumulative incidence of bronchial asthma was from 20.16‰ to 37.2‰, while in some age subgroups this figure exceeds 50 ‰. Determined that for 2022 in Ulaanbaatar - 4.39% and 2.66%, in Darkhan - 2.89% and 2.02%, in Sukhbaatar - 2.91% and 3.72% of patients were diagnosed with allergic rhinitis and bronchial asthma, respectively. In the cities of Ulaanbaatar and Darkhan, the number of patients registered with allergic rhinitis is 1.5 times higher than the number of patients with bronchial asthma, but in the city of Sukhbaatar the opposite trend is observed.

The prevalence of bronchial asthma in the city of Sukhbaatar is much higher than in other cities, higher than in the AR, and as the population ages, this indicator only increases in the group 0 - 10 years - the prevalence of bronchial asthma is 12.72‰, which 2 times higher than the figure in Darkhan - 6.9‰ and 1.5 times higher than in Ulaanbaatar - 8.1 ‰.

Conclusions: taking into account the climatic, geographic, population and epidemiological characteristics of Mongolia, the use of Antipollin for sublingual immunotherapy is the optimal solution that can improve the quality of life of thousands of patients suffering from allergic diseases of the respiratory tract.

About the authors

Pavel Berezhanskiy

People’s Friendship University of Russia named after Patrice Lumumba, Moscow, Russian Federation.

Email: bpvnever@gmail.com
ORCID iD: 0000-0001-5235-5303
SPIN-code: 1480-9900
Scopus Author ID: 57222557502

PhD, Assistant at the Department of Clinical Immunology, Allergology and Adaptology.

Russian Federation, 117198, Moscow, st. Miklouho-Maclay, 6.

Bayarma Tuvshinbayar

People’s Friendship University of Russia named after Patrice Lumumba, Moscow, Russian Federation.

Email: bayarmaa888@yahoo.com

Graduate Student, Department of Clinical Immunology, Allergology and Adaptology

Baygalmaa Sangidorj

National Dermatology Center of Mongolia.

Email: baigalmaas@yahoo.com

PhD, Head of the laboratory of allergology 

Tamara Uskova

People’s Friendship University of Russia named after Patrice Lumumba, Moscow, Russian Federation.

Email: tamara.uskova.2002@mail.ru

laboratory assistant, Department of Clinical Immunology, Allergology and Adaptology

Natalya Tataurschikova

People’s Friendship University of Russia named after Patrice Lumumba, Moscow, Russian Federation.

Author for correspondence.
Email: natalytataur@yandex.ru

MD, Prof., Head of the Department of Clinical Immunology, Allergology and Adaptology

References

  1. Berezhansky P.V. Identification of risk factors for the occurrence of rhinitis in children of different ages living in the Central Federal District // Modern science: current problems of theory and practice. Series: Natural and technical sciences. –2022. –№ 10. – pp. 167–182
  2. Buinova S.N., Chernyak B.A. Dynamics of the prevalence of allergic rhinitis in children of Irkutsk // Russian Journal of Allergy. – 2019. – Vol. 16. – № 1S. – рр. 42–44.
  3. Zhukova N.V., Kilessa V.V., Kostyukova E.A., Shkadova M.G. Allergen–specific immunotherapy. Crimean therapeutic journal. – 2021.№ 3. – Р. 11–16.
  4. Kozulina I.E., Pavlova K.S., Kurbacheva O.M., Clinical effectiveness of subcutaneous and sublingual allergen–specific immunotherapy for allergic rhinitis and conjunctivitis. Russian Allergological Journal. – 2016. –№ 6. P.62–68.
  5. Krylova, T. A.,Zavaliy M. A., Balabantsev A. G. Differential diagnosis of allergic and non–allergic chronic rhinitis / T. A. Krylova, // Journal of Practical Medicine. – 2015. – No. 2 (87). – pp. 13 – 18.
  6. Tataurshchikova N.S., Maksimova A.V. Allergen-specific immunotherapy: search for effective solutions // Effective pharmacotherapy. – 2023. – № 19(26). – рр.34–42.
  7. Tataurshchikova NS, Sangidorzh B. The role of local immunotherapy in the treatment of the patients presenting with virus–associated allergic rhinitis. RussianBulletinofOtorhinolaryngology. – 2017. – № 6 (82). – pp. 60–62.(InRuss.)
  8. Tataurshchikova N.S. Features of the use of tableted Antipollin tablets in people with respiratory allergies. Allergologyandimmunology. – 2014. – № 15 (3).– pp. 177–180.
  9. Terekhina T.A. Quarantine weeds of the South Siberia. Problems of botany in the South Siberia and Mongolia. XIV InternationalScientificandPracticalConference. Barnaul, – 2015. – pp.41–46.
  10. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. ClinTranslAllergy. –2012. – Vol.2. – №1. – P.20.
  11. Luo Z., Akdis F. The past, present, and future of allergic diseases in China. Allergy. – 2022. – Vol.77. – №2. – pp. 354–356.
  12. Penagos, M. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta – analysis of randomized, placebo – controlled, double – blind trials / M. Penagos, E. Compalati, F. Tarantini et al. // Annals of Allergy, Asthma and Immunology. – 2006. – Vol. 97. – №2, – P. 141 – 148.
  13. Shen Y., Zeng J., Hong S., Kang H. Prevalence of allergic rhinitis comorbidity with asthma and asthma with allergic rhinitis in China: A meta–analysis. – 2019. – Vol. 37. – №4. – pp.220–225.
  14. Tataurschikova N.S., Berezhansky P.V. Some features of the key phenotypes of allergic rhinitis among children in a metropolis. Advanced Technologies for Sustainable Development of Urban Green Infrastructure. Proceedings of Smart and Sustainable Cities 2021,рр.202–208.
  15. Viinanen A., Munhbayarlah S., Zevgee T., Narantsetseg L., Naidansuren Ts., Koskenvuo M., Helenius H., Terho E.O.Prevalence of asthma, allergic rhinoconjunctivitis and allergic sensitization in Mongolia.Allergy. – 2005. – Vol.60. – №11. – pp.1370–7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Berezhanskiy P., Tuvshinbayar B., Sangidorj B., Uskova T., Tataurschikova N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies